Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients

Journal article published in 2017 by Stefano Cascinu, Alberto Zaniboni, Gerardo Rosati, Guglielmo Nasti, Sara Lonardi, Paolo Marchetti, Francesco Leone, Domenico Bilancia, Rosario Vincenzo Iaffaioli, Vittorina Zagonel, Monica Giordano, Domenico C. Corsi, Francesco Ferraú, Roberto Labianca, Monica Ronzoni and other authors. Stefano Cascinu, Alberto Zaniboni, Gerardo Rosati, Guglielmo Nasti, Sara Lonardi, Paolo Marchetti, Francesco Leone, Domenico Bilancia, Rosario Vincenzo Iaffaioli, Vittorina Zagonel, Monica Giordano, Domenico C. Corsi, Francesco Ferraú, Roberto Labianca, Monica Ronzoni, Mario Scartozzi, Francesca Galli, Adriana Romiti, Massimo Aglietta, Stefania Mosconi, Luca Gianni , Eliana Rulli, Davide Poli, Valter Torri, Irene De Simone, Fabio Galli, Felice Pasini, Giovanni Rangoni, Raffaele Venezia, Pietro Sozzi, Antonio Nuzzo, Rossana Berardi, Luciano Frontini, Silvia Rota, Lorena Cozzi

Show less

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Preprint: archiving allowed

Upload

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by